MedTrace Logo

A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease

NCT03112096 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-12-14

No results posted yet for this study

Summary

This is a study to evaluate biodistribution, pharmacokinetics and safety of \[18F\]THK-5351 positron emission computed tomography in Cognitively Healthy Subjects and Patients with Alzheimer's Disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

[18F]THK-5351

Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain

Sponsors & Collaborators

  • Asan Foundation

    lead OTHER

Principal Investigators

  • JaeEun Kim · Asan Foundation

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-17
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03112096 on ClinicalTrials.gov